<DOC>
	<DOCNO>NCT00715286</DOCNO>
	<brief_summary>To determine impact Neoadjuvant chemotherapy surgical debulking rate , overall disease-free survival quality life ( QOL ) patient advanced EOC .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Advanced Epithelial Ovarian Cancer ( EOC ) : A Phase III Randomized Study</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<criteria>Age:20 65 year Epithelial ovarian carcinoma Stage IIIc &amp; IV ( pleural effusion ) ECOG PS 02 Cytology/biopsy positive patient Good compliance Previously untreated patient Any medical contraindication surgery Psychiatric illness Cardiac , liver renal dysfunction</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>epithelial ovarian cancer</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>randomize study</keyword>
</DOC>